Valuation: Summit Corporation plc

Market Cap 895.57Cr 1.2TCr 1.05TCr 960.8Cr 1.7TCr 1,13900Cr 1.72TCr 12TCr 4.48TCr 56TCr 4.49TCr 4.39TCr 1,92900Cr P/E 2026 *
-13.6x
P/E 2027 * -13.7x
Enterprise Value 869.4Cr 1.16TCr 1.01TCr 932.72Cr 1.65TCr 1,10500Cr 1.67TCr 11TCr 4.35TCr 54TCr 4.36TCr 4.26TCr 1,87200Cr EV / Sales 2026 *
3,552x
EV / Sales 2027 * 213x
Free-Float
16.86%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 25/07/2022
Chief Executive Officer 81 01/04/2020
Director of Finance/CFO 48 02/04/2024
Director TitleAgeSince
Chairman 81 01/02/2020
Director/Board Member 48 01/12/2019
Director/Board Member 54 11/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.68%+5.92%+77.86%+136.97% 5.91TCr
+2.32%+5.03%+75.26%+92.31% 5.52TCr
+3.86%+6.93%-11.32%-10.57% 2.47TCr
+4.30%+7.95%+14.11%+440.44% 2.42TCr
+4.74%+13.68%+43.36%-3.82% 1.97TCr
-0.29%+9.78%+43.90%-29.12% 1.76TCr
0.00%+20.78%+186.15%+347.42% 1.62TCr
+6.72%+19.38%+37.85% - 1.48TCr
+3.50%+1.97%+21.02%+193.33% 1.4TCr
Average +2.87%+8.57%+54.24%+145.87% 2.73TCr
Weighted average by Cap. +2.46%+6.47%+58.32%+135.90%

Financials

2026 *2027 *
Net sales 24.48L 32.68L 28.57L 26.26L 46.42L 31Cr 47.13L 3.15Cr 1.23Cr 15Cr 1.23Cr 1.2Cr 53Cr 4.2Cr 5.61Cr 4.91Cr 4.51Cr 7.97Cr 534.43Cr 8.09Cr 54Cr 21Cr 262.7Cr 21Cr 21Cr 905.24Cr
Net income -66Cr -88Cr -77Cr -71Cr -124.68Cr -8.36TCr -126.57Cr -846.65Cr -329.13Cr -4.11TCr -329.5Cr -322.42Cr -14TCr -68Cr -91Cr -79Cr -73Cr -129.05Cr -8.65TCr -131.01Cr -876.31Cr -340.66Cr -4.25TCr -341.04Cr -333.72Cr -15TCr
Net Debt -26Cr -35Cr -31Cr -28Cr -50Cr -3.33TCr -50Cr -337.06Cr -131.03Cr -1.64TCr -131.18Cr -128.36Cr -5.64TCr -1.1Cr -1.48Cr -1.29Cr -1.19Cr -2.1Cr -140.48Cr -2.13Cr -14Cr -5.53Cr -69Cr -5.54Cr -5.42Cr -237.96Cr
Logo Summit Corporation plc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-